Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study to Assess the Effectiveness, Safety Profile and Real-life Prescribing and Utilization Patterns of Tildrakizumab (Ilumetri®) in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice. (SAIL)

NCT04203693 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT04203693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04203693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study to Assess the Effectiveness, Safety Profile and Real-life Prescribing and Utilization Patterns of Tildrakizumab (Ilumetri®) in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice. (SAIL)
Lead sponsor
Almirall, S.A.
Phase
Observational
Overall status
Completed
Start date
October 30, 2019
Completion date
May 2, 2024
Enrollment
331 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis